| Overview |
| bs-11530R-FITC |
| LAR/PTPRF Polyclonal Antibody, FITC Conjugated |
| FCM, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Possible cross-reactivity with PTPRS and PTPRD |
| Human |
| Mouse, Rat, Dog, Cow, Sheep, Horse, Rabbit |
| Specifications |
| FITC |
| Rabbit |
| KLH conjugated synthetic peptide derived from human PTPRF |
| 30-100/1907 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 5792 |
| P10586 |
| Cell membrane |
| LAR; LAR protein; LARFN5C; LARS; LCA homolog; Leukocyte antigen related LAR PTP receptor; Leukocyte antigen related; Leukocyte antigen related PTP receptor; Leukocyte antigen related tyrosine phosphatase; Leukocyte common antigen related; Protein Tyrosine Phosphatase Receptor Type F; Protein tyrosine phosphatase receptor type F polypeptide; Ptprf; PTPRF protein; PTPRF_HUMAN; Receptor linked protein tyrosine phosphatase LAR; Receptor type tyrosine protein phosphatase F; Receptor type tyrosine protein phosphatase F precursor; Receptor-type tyrosine-protein phosphatase F. |
| Possible cell adhesion receptor. It possesses an intrinsic protein tyrosine phosphatase activity (PTPase).The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. |
| Application Dilution |
| FCM |
1:20-100 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz